Project/Area Number |
11671224
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | YAMANASHI MEDICAL UNIVERSITY |
Principal Investigator |
KONO Koji YAMANASHI MEDICAL UNIVERSITY, FACULTY OF MEDICINE, DEPARTMENT OF SURGERY, RESEARCH ASSOCIATE, 医学部, 助手 (40283204)
|
Project Period (FY) |
1999 – 2000
|
Project Status |
Completed (Fiscal Year 2000)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,900,000)
Fiscal Year 2000: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 1999: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
Keywords | Gastric cancer / Dendritic cells / Tumor vaccination / immunotherapy / HER-2 / neu |
Research Abstract |
We have previously reported that HER-2/neu-derived peptides are HLA-A0201-restricted CTL epitopes in gastric cancer. We performed tumor vaccination therapy against gastric cancer patients with recurrent tumor using dendritic cells (DC) pulsed with the HER-2/neu peptides. Tumor vaccination therapy were performed HLA-A0201 + patients (n=9) who had a HER-2/neu-overexpressing gastric cancer detected by immunohistochemistry. Plastic adherent cells from PBMC were cultured for 1 week with GM-CSF and IL-4 to generate DC.DC pulsed with HER-2/neu peptides were injected to the patients four times at every 2 weeks intradermaly. Patients received tumor vaccination showed no side effect. In six of them, peptide-specific CTLs were generated from PBMC after tumor vaccination, but not before tumor vaccination. Three of them showed DTH response against vaccinated peptide after tumor vaccination. One of them indicated partial response in metastatic lymph-node after tumor vaccination, paralleling the decrease of tumor marker. One of them showed no change and rest of them (n=7) revealed progressive desease. These observations implicate HER-2/neu-based tumor vaccination as a potential candidate for novel immunotherapy against gastric cancer.
|